The Genetic Influence on the Antihypertensive and Uricosuric Actions of Losartan
Clicks: 123
ID: 276397
2022
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
0.3
/100
1 views
1 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Hypertension (HTN), a globally prevalent non-communicable chronic disease (NCCD), is an international health concern. HTN has multifaceted pathogenesis with a varied prevalence across the globe. Excessive oxidative stress is the underlying cause of imbalance of the Renin Angiotensin Aldosterone System (RAAS) leading to elevated blood pressure (BP). Evidence-based medicine (EBM) along with suitable lifestyle modifications assists in managing the disease, lowering the risk of disease-associated cardiovascular morbidity and mortality. Losartan, an angiotensin receptor blocker (ARB), is one of the first-line drugs available. One of the complications of HTN is hyperuricemia, a metamorphosis in urate homeostasis. Studies have highlighted the uricosuric action of losartan along with its antihypertensive effects. However, varied therapeutic outcomes are observed in patients due to genetic polymorphisms based on different ethnical backgrounds. The present review focuses on the single nucleotide polymorphisms (SNPs) and the degree to which they affect losartan’s antihypertensive and serum uric acid (SUA) lowering effects.| Reference Key |
Aamir2022precisionThe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Eman Aamir;Hareem Arif Siddiqui;Aemen Haroon; |
| Journal | Precision Medicine Communications |
| Year | 2022 |
| DOI | 130 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.